Method for the utilization of and product containing inactivated probiotic
View Patent ↗A children's or infant's nutritional product utilizing or containing one or more inactivated probiotics for preventing or reducing systemic and/or respiratory inflammation in a child or infant.
1. A method for preventing ubiquination of I-kappa-β (Ikβ) in an infant experiencing gastrointestinal inflammation comprising the step of administering a nutritional composition to the infant, wherein the nutritional composition is formulated to deliver from between about 1×10 4 to about 1×10 10 cells of inactivated Lactobacillus rhamnosus GG per kg body weight per day.
2. The method of claim 1 , wherein the nutritional composition further comprises at least one long-chain polyunsaturated fatty acid (LCPUFA).
3. The method of claim 2 , wherein the LCPUFA is selected from the group consisting of docosahexaenoic acid (DHA) and arachidonic acid (ARA).
4. The method of claim 3 , wherein the ratio of ARA:DHA is between about 2:3 and about 2:1.
5. The method of claim 3 , wherein the docosahexanoic acid is present in the nutritional composition in an amount to provide between about 3 mg to about 150 mg per kg of body weight per day.
6. The method of claim 3 , wherein the arachidonic acid is present in the nutritional composition in an amount to provide between about 3 mg to about 150 mg per kg of body weight per day.
7. The method of claim 1 , wherein the nutritional composition further comprises a prebiotic.
8. The method of claim 1 , wherein the infant is a preterm infant.
9. The method of claim 1 , wherein the nutritional composition further comprises a carbohydrate source.
10. The method of claim 1 , wherein the nutritional composition further comprises a protein source.
11. The method of claim 1 , wherein the nutritional composition further comprises a lipid source.
12. A method reducing the translocation of nuclear factor-kB (NFkB) in an infant experiencing gastrointestinal inflammation, the method comprising the step of administering between about 1×10 4 to about 1×10 10 cells of inactivated Lactobacillus rhamnosus GG per kg body weight per day.
13. The method of claim 12 , wherein the cells of inactivated Lactobacillus rhamnosus GG are formulated in a nutritional composition.
14. The method of claim 12 , further comprising the step of administering to the infant between about 3 mg to about 150 mg per kg of body weight per day docosahexanoic acid.
15. The method of claim 12 , further comprising the step of administering to the infant between about 3 mg to about 150 mg per kg of body weight per day arachidonic acid.
16. The method of claim 13 , wherein the nutritional composition further comprises a prebiotic.
17. The method of claim 12 , wherein the infant is a preterm infant.
18. The method of claim 13 , wherein the nutritional composition further comprises a carbohydrate source.
19. The method of claim 13 , wherein the nutritional composition further comprises a protein source.